Department of Neurosurgery, Louisiana State University Health Sciences Center at Shreveport, Shreveport, Louisiana, USA.
World Neurosurg. 2011 May-Jun;75(5-6):660-4. doi: 10.1016/j.wneu.2011.02.019.
Hypertension, hypervolemia, and hemodilution [HHH] therapy is widely used for prophylactic and therapeutic means in the setting of angiographic or clinical cerebral vasospasm. Hemodilution remains the most controversial aspect of the HHH therapy.
We performed a literature review to identify the current state of support for hemodilution as a therapeutic modality in treatment of cerebral vasospasm.
Over time, evidence has been accumulating against the efficacy of HHH therapy and hemodilution in particular. Although HHH therapy and consequently hemodilution has wide support, the evidence for its effectiveness remains equivocal.
At the time of this study, the burden of evidence appears to be tipped away from hemodilution as a therapeutic modality.
高血压、血容量过多和血液稀释[HHH]疗法在血管造影或临床脑血管痉挛的预防性和治疗性措施中被广泛应用。血液稀释仍然是 HHH 治疗中最具争议的方面。
我们进行了文献回顾，以确定血液稀释作为治疗脑血管痉挛的治疗方法的当前支持状态。
随着时间的推移，越来越多的证据表明 HHH 治疗，特别是血液稀释，无效。尽管 HHH 治疗和因此血液稀释得到了广泛的支持，但它的有效性仍然存在争议。
在本研究时，证据的负担似乎倾向于将血液稀释作为一种治疗方式。
